She is a Fellow of the Royal College of Physicians, the American Heart Association, the Academy of Medical Sciences, the Royal Society of Edinburgh, the European Society of Cardiology and the Society of Biology.

She leads a triple helix partnership between academia, the NHS and industry to accelerate innovation, maximise patient benefit and stimulate business growth, including a collaboration of four Scottish universities, four NHS Health Boards across Scotland and two major industry partners in a public/private partnership focused on precision medicine. Professor Dominiczak is the driving force behind the fundraising, development and delivery of the University’s clinical academic campus at Queen Elizabeth University Hospital in Glasgow, comprising Clinical Research Facilities a Teaching and Learning Centre a state-of-the-art Imaging Centre of Excellence (including the UK’s first 7Tesla MRI scanner in a clinical setting) and a Clinical Innovation Zone. Her major research interests are in hypertension, cardiovascular genomics and precision medicine, where she not only publishes extensively in top peer-reviewed journals (over 500 publications), but also excels in large scale research funding for programmes and infrastructure (with a total value in excess of £100M over the last eight years). Recognised as a world-leading cardiovascular scientist and clinical academic, she held a British Heart Foundation Chair of Cardiovascular Medicine at University of Glasgow between 19, and directorship of the Cardiovascular Research Centre between 20. In 2016, she was awarded a DBE for services to cardiovascular and medical science. She is also an Honorary Consultant Physician and Non-Executive Member of NHS Greater Glasgow and Clyde Health Board and Health Innovation Champion for the Medical Research Council. Professor Dame Anna Dominiczak DBE, MD, FRCP, FAHA, FRSE, FMedSci is Regius Professor of Medicine, Vice Principal and Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.ĭame Anna Dominiczak, DBE, MD, FRCP, FAHA, FRSE, FMedSci Regius Professor of Medicine, Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, University of Glasgow While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.ĭr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. He also currently serves on the Board of ASCO’s Conquer Cancer Foundation. Burris served as president of ASCO in 2019-2020 and is serving as Chair of the Board for the 2020-2021 term. He has authored over 400 publications and 700 abstracts.ĭr.

In 1997, he established in Nashville the first community – based early phase drug development program, which grew into the Sarah Cannon Research Institute.

He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.ĭr. Burris’ clinical research career has focused on the development of new cancer agents with an emphasis on first – in – human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved. “Skip” Burris III, MD, FASCO, FACP serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for Sarah Cannon Research Institute. “Skip” Burris III, MD, FASCO, FACP Chief Medical Officer, Sarah Cannon, Executive Director, Drug Development, Sarah Cannon Research Institute

Pharmacogenomics & Pharmacovigilance in Precision Medicine.

International Conference on Newborn Sequencing.

Updates in Precision Medicine: Pharmacogenomics and Pharmacovigilance.

Medical conferences 2016 chicago